Log in

Start Your Membership Now

Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced that effective January 1, 2020, William H. Carson, M.D., president and chief executive officer (CEO) will retire from the company’s operational leadership. Dr. Carson will transition to Chairman of the OPDC Board of Directors, as well as spearhead Otsuka philanthropic initiatives to be announced in 2020.

Dr. Carson joined Otsuka in 2002 as a board-certified psychiatrist. During his tenure, Dr. Carson has helped OPDC realize the promise of various compounds, leading the way from clinical trials to commercialization of products that include SAMSCA® (tolvaptan), ABILIFY MAINTENA® (aripiprazole), REXULTI® (brexpiprazole . . .

Want To Read More? Log In Or Become A Free Member
Resource Available For All OPEN MINDS Circle Members
Log In
If you are already a member, log in to your account to access this resource and more.

Become A Free Member
You can become a free member and get access now. Learn more about the OPEN MINDS Circle Market Intelligence Service Membership. Reach out to our team at info@openminds.com, or call us at 877-350-6463.

A Paid OPEN MINDS Circle Membership provides unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!

Tagged As: